The October 2022 updates to the Chapter 53 of the FDAs Post-marketing Adverse Drug Experience (PADE) Inspection Manual resulted in a few key changes. We’ve helped our clients prepare, oftentimes mobilizing not only within PV, but across cross-functional partners (ex. MedInfo, Quality, Marketing, Regulatory, & Legal). While PADE inspections build upon the successes (or shortcomings) … Read more
SSI Strategy is thrilled to welcome Fiore Healthcare Advisors (FHA) to the team! The acquisition of Fiore Healthcare Advisors (FHA) aligns with our growth goals and further expands our Pharmacovigilance and Clinical Research offerings by onboarding a team of medical experts to further support our clients. Read The Press Release »
SSI Strategy + Medocity Partnership SSI has partnered with the leading virtual care technology platform, Medocity, bringing together Medical expertise and the innovative Medocity platform to help solve our client’s most ambitious challenges. The Medocity platform enables continuous digital care between visits for patients with complex and chronic conditions, connecting patients and care teams in … Read more
Organizations often struggle to articulate the value of the Medical Office. As a leader in life sciences consulting, SSI Strategy continues to advance the dialog of how to quantify the metric of value and offers guidance for optimizing it in the context of the Medical Office. Though SSI Strategy believes that no single formula can accurately reflect … Read more